Stockpolly
Search
ATHE · NASDAQ · Biotechnology

Alterity Therapeutics (ADR) (ATHE)

Develops ATH434, a clinical candidate for multiple system atrophy and related Parkinsonian disorders.

$4.55
At close0.00 (0.00%)
Watchlist

In millions of USD, except per-share figures · converted from AUD at the latest rate

In millionsQ2 FY21Dec 2020Q4 FY21Jun 2021Q2 FY22Dec 2021Q4 FY22Jun 2022Q2 FY23Dec 2022Q4 FY23Jun 2023Q2 FY24Dec 2023Q4 FY24Jun 2024Q2 FY25Dec 2024Q4 FY25Jun 2025Q2 FY26Dec 2025Q4 FY26Jun 2026
Revenue122221121300
Cost of revenue000000000000
Gross profit122221111300
77788661168911
Research & development455664594667
322222122244
Selling & marketing000000000000
General & administrative332222122200
Other expenses000000000000
Operating income−7−7−7−8−8−6−3−9−5−5−9−11
−1111000−1−1201
Interest income000000000011
Other non-operating income1−1−1−100000000
Income before tax−8−6−6−6−7−5−3−11−6−4−9−11
Income tax expense−1−2−2−2−2−1−1−1−10−2−1
Net income from continuing operations−6−5−5−5−6−4−5−9−5−4−7−10
Net income−6−5−5−5−6−4−5−9−5−4−7−10
EPS, basic−$2.80−$1.38−$1.17−$1.12−$1.42−$1.04−$1.12−$0.86−$0.60−$0.30−$0.39−$0.56
EPS, diluted−$2.80−$1.38−$1.17−$1.12−$1.42−$1.04−$1.12−$0.86−$0.60−$0.30−$0.39−$0.56
Weighted average shares, basic2344444119121718
Weighted average shares, diluted2344444119121718
EBITDA−7−6−6−6−7−5−6−11−5−5−9−11
Depreciation & amortization000000000000
EBIT−8−6−6−6−7−5−6−11−5−5−9−11